Benitec settles another lawsuit
Tuesday, 24 August, 2004
RNAi company Benitec (ASX: BLT) has settled its second patent infringement lawsuit in two weeks, giving US company Genscript Corporation a non-exclusive worldwide licence to manufacture and sell DNA-directed RNAi (ddRNAi) products.
The lawsuit was one of three filed on March 22, 2004 against US companies Ambion, Genscript and Nucleonics. Ambion was granted a licence as part of a settlement announced on August 10. Financial details of the settlement and licence were not disclosed.
The company has also been granted a second UK patent related to its ddRNAi technology for use of ddRNAi expressed as hairpins in vertebrate animal cells, bringing the number of issued patents in the company's portfolio to eight.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
